Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

GSK discontinues development of Kissei's SGLT2 inhibitor remogliflozin for diabetes

July 7, 2009

Fate Therapeutics acquires intellectual property rights to osteogenic agents from UC

July 7, 2009

Rosiglitazone combination therapy increases the risk of heart failure but not CV mortality

July 6, 2009

European Commission grants marketing authorization for Novo Nordisk's Victoza

July 6, 2009

Tekmira initiates phase I human clinical trial of ApoB SNALP for LDL cholesterol

July 6, 2009

Phase III data show significant effects of DX-88 on hereditary angioedema attacks

July 6, 2009

Repros scheduled to discuss phase III clinical program for Proellex with the FDA

July 3, 2009

Pharming presents results from final analysis of Rhucin studies

July 3, 2009

Studies assess ghrelin in healthy men, frail older women, hip replacement patients

July 3, 2009

European CHMP recommends marketing authorization for Tigenix's ChondroCelect

July 2, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
Biotle’s FcRn inhibitor BTL-203 cleared for clinic in China
BioWorld Science
Biotle has received a clinical trial notice from China’s National Medical Products Administration (NMPA) for its IND application for BTL-203, the company’s...